ZyVersa Therapeutics Financials
| ZVSA Stock | 1.07 0.04 3.60% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.24 | 0.3289 |
|
|
Investors should never underestimate ZyVersa Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor ZyVersa Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in ZyVersa Therapeutics.
Net Income |
|
ZyVersa | Select Account or Indicator |
Understanding current and past ZyVersa Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ZyVersa Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in ZyVersa Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of ZyVersa Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ZyVersa Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ZyVersa Therapeutics' management manipulating its earnings.
ZyVersa Therapeutics Stock Summary
ZyVersa Therapeutics competes with Cns Pharmaceuticals, Immix Biopharma, Hepion Pharmaceuticals, and Zura Bio. ZyVersa Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 51724W107 98987D102 98987D201 98987D300 |
| Location | New Jersey; U.S.A |
| Business Address | 2200 N Commerce |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.zyversa.com |
| Phone | 754 231 1688 |
ZyVersa Therapeutics Key Financial Ratios
| Return On Equity | -1.52 | ||||
| EBITDA | (107.74 M) | ||||
| Net Income | (98.3 M) | ||||
| Book Value Per Share | 27.33 X | ||||
| Market Capitalization | 2.51 M |
ZyVersa Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ZyVersa Therapeutics's current stock value. Our valuation model uses many indicators to compare ZyVersa Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ZyVersa Therapeutics competition to find correlations between indicators driving ZyVersa Therapeutics's intrinsic value. More Info.ZyVersa Therapeutics is rated below average in return on equity category among its peers. It is rated second in return on asset category among its peers . At present, ZyVersa Therapeutics' Return On Equity is projected to drop based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ZyVersa Therapeutics' earnings, one of the primary drivers of an investment's value.ZyVersa Therapeutics Systematic Risk
ZyVersa Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ZyVersa Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on ZyVersa Therapeutics correlated with the market. If Beta is less than 0 ZyVersa Therapeutics generally moves in the opposite direction as compared to the market. If ZyVersa Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ZyVersa Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ZyVersa Therapeutics is generally in the same direction as the market. If Beta > 1 ZyVersa Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in ZyVersa Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ZyVersa Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ZyVersa Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
ZyVersa Therapeutics November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ZyVersa Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ZyVersa Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of ZyVersa Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing ZyVersa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ZyVersa Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 78.93 | |||
| Value At Risk | (9.60) | |||
| Potential Upside | 7.57 |
Complementary Tools for ZyVersa Stock analysis
When running ZyVersa Therapeutics' price analysis, check to measure ZyVersa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZyVersa Therapeutics is operating at the current time. Most of ZyVersa Therapeutics' value examination focuses on studying past and present price action to predict the probability of ZyVersa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZyVersa Therapeutics' price. Additionally, you may evaluate how the addition of ZyVersa Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |